Poolbeg PharmaPOLBF -20.36% EV-to-FCF is -8.00 as of Jun. 25, 2026. The stock has 1 warning sign investors should review. Among 330 Biotechnology companies, Poolbeg Pharma ranks worse than 303030% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Poolbeg Pharma's Enterprise Value is $52.18 Mil.
Poolbeg Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $-6.53 Mil. Therefore, Poolbeg Pharma's EV-to-FCF for today is -8.00.
The historical rank and industry rank for Poolbeg Pharma's EV-to-FCF or its related term are showing as below:
POLBF'
s EV-to-FCF Range Over the Past 10 Years
Min: -9.48 Med: 0 Max: 0
Current: -9.48
POLBF's EV-to-FCF is ranked worse than 100% of 330
companies
in the Biotechnology industry
Industry Median: 14.97
vs POLBF: -9.48
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Poolbeg Pharma's PE Ratio (TTM) for today is calculated as:
Poolbeg Pharma's share price for today is $0.0919.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Poolbeg Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.013.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Poolbeg Pharma EV-to-FCF Related Terms
Poolbeg Pharma EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Poolbeg Pharma's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Poolbeg Pharma's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Poolbeg Pharma EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Poolbeg Pharma's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Poolbeg Pharma's EV-to-FCF falls into.
Poolbeg Pharma's current Enterprise Value is $52.18 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Poolbeg Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $-6.53 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Poolbeg Pharma (POLBF) has a EV-to-FCF of -8.00 as of Jun. 25, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Poolbeg Pharma and its competitors. According to the industry distribution chart, Poolbeg Pharma ranks #999999 out of 330 companies in the Biotechnology industry.
Is Poolbeg Pharma's EV-to-FCF too high?
Poolbeg Pharma's current EV-to-FCF is -8.00. Based on the distribution chart, Poolbeg Pharma ranks #999999 out of 330 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Poolbeg Pharma's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Poolbeg Pharma ranks #999999 out of 330 companies for EV-to-FCF. This places Poolbeg Pharma in the lower half of its industry. The industry median EV-to-FCF is 14.97. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 14.97, based on 330 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Poolbeg Pharma and its competitors. For the Biotechnology industry, the median EV-to-FCF is 14.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Poolbeg Pharma's current EV-to-FCF is -8.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Poolbeg Pharma stock overvalued right now?
Poolbeg Pharma (POLBF) has a current EV-to-FCF of -8.00. The current EV-to-FCF is -8.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Poolbeg Pharma (POLBF), the current EV-to-FCF is -8.00 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Poolbeg Pharma PLC is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company's main asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). The group is also advancing the development of a patient-friendly therapy for obesity with an oral encapsulated GLP-1, offering a differentiated approach within one of the world's markets. It is focused on partnering its high-value programmes that are targeting large markets and addressing critical unmet medical needs.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
POLBF has been successfully added to your 